Managers / Q3 2020 · view latest →
Versant Venture Management, LLC
CIK 0001560009 · ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO, CA, 94104 · 650-233-7877
Reported Value
Under review
reported total failed a data-quality check
Positions
11
Filings on Record
30
2019–present window
Filed
Nov 12, 2020
original filing
Summary
Compared with Q2 2020, the fund opened 1 new position and exited 2.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
- Other · 71.2% · $389M
- Common Stock · 28.8% · $158M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| Flexion Therapeutics, Inc. | NEW | +3.84M | 3.84M | +$40M | $40M |
| VCYTVeracyte, Inc. | SOLD OUT | −1.21M | 0 | −$31.2B | $0 |
| OPHTEURIVERIC bio, Inc. | SOLD OUT | −1.72M | 0 | −$8.8B | $0 |
| AKROAkero Therapeutics, Inc. | TRIMMED | −1.34M | 777.7K | −$52.7B | $24M |
| CRISPR Therapeutics AG | TRIMMED | −551.4K | 3.63M | −$307.1B | $304M |
| ADVMCHFAdverum Biotechnologies, Inc. | HELD | +0 | 7.00M | −$146.2B | $72M |
| Aprea Therapeutics, Inc. | HELD | +0 | 1.85M | −$71.9B | $45M |
| CRNXCrinetics Pharmaceuticals, Inc. | HELD | +0 | 2.03M | −$35.5B | $32M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2020
11 positions
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | CRISPR Therapeutics AG | Common Stock | 55.59% | $304M | 3.63M |
| 2 | ADVMCHFAdverum Biotechnologies, Inc.history → | Common Stock | 13.20% | $72M | 7.00M |
| 3 | Aprea Therapeutics, Inc. | Common Stock | 8.17% | $45M | 1.85M |
| 4 | Flexion Therapeutics, Inc. | Common Stock | 7.32% | $40M | 3.84M |
| 5 | CRNXCrinetics Pharmaceuticals, Inc.history → | Common Stock | 5.82% | $32M | 2.03M |
| 6 | AKROAkero Therapeutics, Inc.history → | Common Stock | 4.38% | $24M | 777.7K |
| 7 | OCULOcular Therapeutix, Inc.history → | Common Stock | 3.09% | $17M | 2.22M |
| 8 | 2JQGritstone Oncology, Inc.history → | Common Stock | 1.51% | $8M | 3.10M |
| 9 | CymaBay Therapeutics, Inc. | Common Stock | 0.72% | $4M | 543.8K |
| 10 | CLVSEURClovis Oncology, Inc. | Common Stock | 0.11% | $594,000 | 101.9K |
| 11 | Second Sight Medical Products, Inc. | Common Stock | 0.09% | $484,000 | 561.6K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $141M | 8 | May 5, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $151M | 7 | Feb 12, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $212M | 9 | Nov 10, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $82M | 8 | Aug 11, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $60M | 7 | May 7, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $87M | 7 | Feb 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $64M | 6 | Nov 8, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $77M | 8 | Aug 7, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $103M | 7 | May 3, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $389M | 7 | Feb 8, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $188M | 8 | Nov 3, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $84M | 8 | Aug 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $48M | 7 | May 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $48M | 7 | Feb 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $59M | 8 | Nov 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $65M | 8 | Aug 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $100M | 10 | May 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $187M | 10 | Feb 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $242M | 11 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $302M | 11 | Aug 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $513M | 11 | May 7, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $963M | 12 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | Under review | 11 | Nov 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $696.1B | 12 | Jul 20, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $364.6B | 9 | Apr 28, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $331.8B | 7 | Jan 21, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $258.5B | 8 | Oct 8, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $343.2B | 9 | Jul 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $303.6B | 9 | Apr 5, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $202.0B | 10 | Jan 22, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.